Alessandro Noseda Selected Research

COVID-19

1/2022

Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Noseda Research Topics

Disease

4	Neoplasms (Cancer) 01/2020 - 01/2016
3	Inflammation (Inflammations) 01/2022 - 01/2017
2	Neoplasm Metastasis (Metastasis) 01/2017 - 01/2016
1	Virus Diseases (Viral Diseases) 01/2022
1	COVID-19 01/2022
1	Infections 01/2022
1	Edema (Dropsy) 01/2017
1	Pancreatitis 01/2017

Drug/Important Bio-Agent (IBA)

5	heparanaseIBA 01/2022 - 01/2016
3	roneparstatIBA 01/2022 - 01/2016
2	CytokinesIBA 01/2022 - 01/2017
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Heparin (Liquaemin)FDA LinkGeneric 01/2022
1	Small Cytoplasmic RNAIBA 01/2022
1	VaccinesIBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	AnticoagulantsIBA 01/2022
1	EnzymesIBA 01/2020
1	Proteoglycans (Proteoglycan)IBA 01/2017
1	Glycoside Hydrolases (Endoglycosidases)IBA 01/2017
1	Heparitin Sulfate (Heparan Sulfate)IBA 01/2017
1	CeruletideIBA 01/2017
1	OligosaccharidesIBA 01/2017
1	Sulfates (Sulfates, Inorganic)IBA 01/2017
1	carfilzomibIBA 01/2016
1	NF-kappa B (NF-kB)IBA 01/2016
1	Conditioned Culture MediaIBA 01/2016
1	Bortezomib (Velcade)FDA Link 01/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016

Therapy/Procedure

3	Therapeutics 01/2022 - 01/2016
2	Drug Therapy (Chemotherapy) 01/2016 - 01/2016